Argenx
Clinical trials sponsored by Argenx, explained in plain language.
-
Promising POTS drug study halted early – what we know
Disease control TerminatedThis study looked at the long-term safety of a drug called efgartigimod for adults with post-COVID postural orthostatic tachycardia syndrome (POTS), a condition that causes dizziness and rapid heartbeat when standing. It enrolled 33 people who had completed a previous study. The …
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
Thyroid eye disease drug trial halted: no safety concerns, but not effective enough
Disease control TerminatedThis study tested a drug called efgartigimod for adults with moderate-to-severe thyroid eye disease, a condition that causes bulging eyes and vision problems. The trial was stopped early because early results showed it was unlikely to work well enough. The drug was found to be sa…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Thyroid eye disease drug trial halted early – no safety worries
Disease control TerminatedThis study tested a drug called efgartigimod for adults with moderate-to-severe thyroid eye disease. About 105 people were expected to join, but the trial was stopped early because early results showed the drug likely wouldn't work well enough. Importantly, there were no safety c…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug shows promise for blistering skin disease, but Long-Term use needed
Disease control TerminatedThis study looked at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who completed an earlier study could receive the drug for up to 48 weeks, with the option to pause…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 13, 2026 16:02 UTC